Senate Confirms Califf as F.D.A. Chief in Tight Vote
The narrow 50-46 decision underscored the divisions on both sides of the aisle over agency policies on opioids and abortion medications and his ties to the drug industry.
Covid Drugs May Work Well, but Our Health System Doesn’t
The people who need treatments the most may be the least likely to get them.
F.D.A Delays Review of Pfizer’s Covid Vaccine for Children Under 5
The agency will wait for data on whether three doses of Pfizer-BioNTech’s Covid vaccine are effective in young children after new, disappointing data.
F.D.A. Clears Monoclonal Antibody Drug From Eli Lilly
The federal government has ordered 600,000 doses of the monoclonal antibody treatment, which is meant for high-risk Covid patients early in their illness.
Angry Customers, More Work and Longer Hours Strain Pharmacists
Pharmacists and technicians, who have played a critical role in administering Covid-19 tests and vaccines, say they are burned out nearly two years into the pandemic.
¿Vacunar a los niños pequeños o esperar?
No está claro si tres dosis de la vacuna Pfizer-BioNTech protegerán adecuadamente a los niños. Pero es posible que la FDA autorice las primeras dos dosis de cualquier manera.
FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
The panel debated whether overseas trials could be applied to a more diverse U.S. population. The decision may affect other Chinese drug trials, and spotlights the high cost of immunotherapy.
C.D.C. Proposes New Guidelines for Treating Pain, Including Opioid Use
The agency threw out previous recommended limits on doses but encouraged “nonopioid therapies” wherever possible.
The Next Vaccine Debate: Immunize Young Children Now, or Wait?
It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.
The Next Vaccine Debate: Immunize Young Children Now, or Wait?
It’s not clear whether three doses of the Pfizer-BioNTech vaccine will adequately protect young children. But the F.D.A. may authorize the first two doses anyway.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.